Araujo-Melo M H, Meneses A M, Schubach A O, Moreira J S, Conceição-Silva F, Salgueiro M M, Pimentel M I F, Araújo-Silva M, Oliveira R V C, Carmo C N, Valete-Rosalino C M
Laboratory Surveillance Leishmaniasis, Evandro Chagas Clinical Research Institute, Rio de Janeiro, Brazil.
J Laryngol Otol. 2010 Oct;124(10):1056-60. doi: 10.1017/S0022215110001325. Epub 2010 Jun 11.
To evaluate dizziness in patients receiving meglumine antimoniate for the treatment of mucosal leishmaniasis.
We retrospectively studied 127 patients treated at the Laboratory of Leishmaniasis Surveillance, Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, between 1 January 1989 and 31 December 2004.
A low dose of meglumine antimoniate (5 mg/kg/day) was used in 86.6 per cent of patients; a dose of 10 mg/kg/day or higher was used in 13.4 per cent of patients. Dizziness was reported by 4.7 per cent of patients. The adjusted odds ratios were 7.37 for dizziness in female patients, 4.9 for dizziness in patients aged 60 years or older, and 7.77 for dizziness in the presence of elevated serum lipase.
We suggest that dizziness may be a side effect of meglumine antimoniate, particularly in elderly individuals, in females and in patients with elevated serum lipase.
评估接受葡甲胺锑酸盐治疗黏膜利什曼病患者的头晕情况。
我们回顾性研究了1989年1月1日至2004年12月31日期间在巴西里约热内卢奥斯瓦尔多·克鲁兹基金会埃万德罗·查加斯临床研究所利什曼病监测实验室接受治疗的127例患者。
86.6%的患者使用低剂量葡甲胺锑酸盐（5毫克/千克/天）；13.4%的患者使用10毫克/千克/天或更高剂量。4.7%的患者报告有头晕症状。女性患者头晕的校正比值比为7.37，60岁及以上患者头晕的校正比值比为4.9，血清脂肪酶升高患者头晕的校正比值比为7.77。
我们认为头晕可能是葡甲胺锑酸盐的一种副作用，尤其是在老年个体、女性以及血清脂肪酶升高的患者中。
